WO2020076105A1 - 신규 항-c-kit 항체 - Google Patents
신규 항-c-kit 항체 Download PDFInfo
- Publication number
- WO2020076105A1 WO2020076105A1 PCT/KR2019/013310 KR2019013310W WO2020076105A1 WO 2020076105 A1 WO2020076105 A1 WO 2020076105A1 KR 2019013310 W KR2019013310 W KR 2019013310W WO 2020076105 A1 WO2020076105 A1 WO 2020076105A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- cancer
- seq
- kit
- present
- Prior art date
Links
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/5748—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving oncogenic proteins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
Definitions
- the present invention relates to novel anti-C-KIT antibodies or antibody fragments thereof.
- the present invention relates to a composition for preventing or treating angiogenesis-related diseases, or a kit for diagnosing angiogenesis-related diseases, comprising the anti-C-KIT antibody or an antibody fragment thereof.
- Angiogenesis refers to the mechanism by which new blood vessels are created from existing blood vessels. Abnormal or excessive angiogenesis causes various diseases.
- angiogenesis is one of the causes of tumor growth as well as benign to malignant tumor growth, as well as age-related macular degeneration, diabetic retinopathy, and glaucoma.
- Glaucoma angiogenesis and rheumatoid arthritis
- Psoriasis psoriasis
- Chronic inflammation chronic inflammation
- angiogenesis-related diseases such as hyperplasia of the neovascularization has been reported (Cameliet and Jain, Nature, 407: 249 , 2000).
- angiogenesis inhibitors for this reason, research has been conducted to treat angiogenesis-related diseases using angiogenesis inhibitors, and a number of angiogenesis promoting and inhibiting factors involved in angiogenesis processes such as growth, migration, and differentiation of vascular endothelial cells was found.
- angiogenesis inhibitors can be divided into several categories, including matrix-breakdown inhibitors, endothelial cell inhibitors, and angiogenesis inhibitors, among which the angiogenesis inhibitors Inhibitors include drugs that target VEGFR2, VEGFR1, PDGFR, C-KIT, FLT3, etc., and inhibit their activity, signaling, production, and the like.
- C-KIT one of the targets of the angiogenesis inhibitor, belongs to the class III of the receptor tyrosine kinase (RTK), and is also known as a receptor of the stem cell factor (SCF).
- RTK receptor tyrosine kinase
- SCF stem cell factor
- the SCF binds to and interacts with the ligand binding domain of C-KIT, and as a result, the C-KIT protein is phosphorylated to have activity.
- Cell growth, differentiation and proliferation through signaling processes such as PI3K / AKT system, RAS / MAP kinase, etc. And various biological functions. In particular, it has been reported on the action of SCF / C-KIT stimulation in angiogenesis (Angiogenesis in Health, Disease and Malignancy, pp 33-36).
- C-KIT Commercial drugs targeting C-KIT include gleevec (imatinib mesylate) and sutente (sunitinib malate), but these are multi-targeted therapeutics that inhibit several kinases, resulting in many side effects, low specificity and bioavailability, and antigens. Therapeutic limitations such as sex and inadequate pharmacokinetics have been reported. Accordingly, there is a need to develop a therapeutic agent that is specific to C-KIT and has no side effects and is effective for diseases related to angiogenesis by activation of C-KIT.
- the present inventors tried to find a therapeutic substance for angiogenesis-related diseases, and as a result, specific anti-C-KIT antibodies that specifically bind to C-KIT can significantly inhibit angiogenesis and thus angiogenesis-related. It has been confirmed that it can have excellent treatment ability against diseases and the present invention has been completed.
- an object of the present invention to provide an anti-C-KIT antibody or an antibody fragment thereof having excellent C-KIT inhibitory ability by specifically binding to domain II of the C-KIT protein.
- an object of the present invention is to provide a composition and a diagnostic kit for preventing or treating angiogenesis-related diseases including the anti-C-KIT antibody or antibody fragment thereof.
- the present invention provides an anti-C-KIT antibody or antibody fragment thereof that specifically binds C-KIT.
- the anti-C-KIT antibody or antibody fragment thereof according to the invention specifically binds to domain II of C-KIT.
- antibody refers to an immunoglobulin molecule that is immunologically reactive with a specific antigen or a protein molecule that acts as a receptor specifically recognizing an antigen.
- antibody is used in a broad sense, polyclonal antibodies, monoclonal antibodies, whole antibodies (antibodies consisting of at least two heavy and two light chains interconnected by disulfide bonds), and It is interpreted as including all antibody fragments.
- the full length antibodies include IgA, IgD, IgE, IgM and IgG.
- the IgG may include IgG1, IgG2, IgG3 and IgG4 as subtypes.
- antibody fragment retains at least a portion of the binding specificity of a parent antibody, and an antigen-binding fragment comprising a portion (eg, one or more CDRs) or variable regions of an antigen binding region of a parent antibody, or Means an analog of an antibody.
- the antibody fragment is a multispecific formed from, for example, Fab, Fab ', F (ab') 2, Fv fragment, sc-Fv, unibody, diabody, linear antibody, nanobody, domain antibody or antibody fragment It can be an enemy antibody.
- heavy chain refers to a full-length heavy chain and fragments thereof that include a heavy chain variable region and a heavy chain constant region.
- gamma ⁇
- mu ⁇
- alpha ⁇
- delta ⁇
- epsilon ⁇
- light chain refers to a full-length light chain and fragments thereof that include the light chain variable region and the light chain constant region. There are kappa ( ⁇ ) and lambda ( ⁇ ) types in the light chain.
- the antibody is a full-length antibody or an antibody fragment having antigen-binding ability
- the heavy chain may be any of gamma ( ⁇ ), mu ( ⁇ ), alpha ( ⁇ ), delta ( ⁇ ), or epsilon ( ⁇ ) type
- the light chain may be of kappa ( ⁇ ) or lambda ( ⁇ ) type. According to one aspect of the invention, the light chain is a kappa type.
- C-KIT belongs to class III of the receptor Tyrosine Kinase (RTK) and is also known as a receptor for SCF.
- C-KIT one of the targets of the angiogenesis inhibitor, belongs to class III of the receptor tyrosine kinase (RTK), and is a receptor of the stem cell factor (SCF), which plays an important role in hematopoiesis.
- RTK receptor tyrosine kinase
- SCF stem cell factor
- anti-C-KIT antibody refers to an antibody that specifically binds C-KIT. Specifically, the anti-C-KIT antibody specifically binds to domain II of C-KIT, and thus can inhibit or neutralize the activity or activation of C-KIT.
- the anti-C-KIT antibody or antibody fragment thereof of the present invention is a light chain CDR1 represented by SEQ ID NO: 1, a light chain CDR2 represented by SEQ ID NO: 2, and a light chain represented by SEQ ID NO: 3 And a light chain variable region comprising CDR3.
- the anti-C-KIT antibody or antibody fragment thereof of the present invention is a heavy chain CDR1 represented by SEQ ID NO: 4, a heavy chain CDR2 represented by SEQ ID NO: 5, and a heavy chain represented by SEQ ID NO: 6 Heavy chain variable region comprising CDR3.
- the light chain variable region of the anti-C-KIT antibody or antibody fragment thereof of the present invention comprises the amino acid sequence of SEQ ID NO: 7.
- the heavy chain variable region of the anti-C-KIT antibody or antibody fragment thereof of the invention comprises the amino acid sequence of SEQ ID NO: 8.
- the anti-C-KIT antibody or antibody fragment thereof of the present invention may include a light chain comprising the amino acid sequence of SEQ ID NO: 25.
- the anti-C-KIT antibody or antibody fragment thereof of the present invention may include a heavy chain comprising the amino acid sequence of SEQ ID NO: 26.
- CDR complementarity determining region
- the amino acid sequences of the heavy and light chains each include three CDRs that are non-contiguous, namely heavy chain CDR H1 , CDR H2 , CDR H3 and light chain CDR L1 , CDR L2 , CDR L3 .
- CDR is a site involved in the recognition of the antigen, and provides an important contact residue when the antibody binds to the antigen or epitope, and plays a decisive role in diversity of antigen specificity.
- Antibodies of the present invention or antibody fragments thereof include sequences showing substantial identity to the sequences listed in the Sequence Listing.
- the substantial identity means that the two sequences are aligned so as to correspond as much as possible, and after analysis using an algorithm commonly used in the art, 80%, 90%, or 95% or more of sequences are exhibited.
- the anti-C-KIT antibody of the present invention may include the sequence of the anti-C-KIT antibody described herein, as well as biological equivalents thereof, within a range capable of specifically recognizing and binding C-KIT. You can. For example, it may include additional variations in sequence to improve antibody binding affinity and / or biological properties, etc., and may include additional variations within a range that does not alter the overall activity of the molecule.
- the anti-C-KIT antibody or antibody fragment thereof may comprise a constant region derived from human IgG1.
- the present invention provides a human anti-C-KIT antibody comprising the light chain variable region and the heavy chain variable region and a constant region derived from human IgG1.
- human antibody as used herein is understood to mean an antibody having framework and CDR regions having variable regions derived from human immunoglobulin sequences.
- human antibodies may include amino acid residues that are not encoded by human-derived immunoglobulin sequences (e.g., mutations introduced by random or site-specific mutagenesis in vitro or by somatic mutation in vivo). have.
- the human antibody may be in the form of a full-length antibody or a functional fragment of an antibody molecule. Since all the components of the human antibody are derived from humans, the immune response is less likely to occur when administered to humans compared to humanized antibodies or mouse antibodies. Therefore, it has an advantageous advantage as a therapeutic antibody for humans.
- the anti-C-KIT antibody or antibody fragment thereof of the present invention effectively prevents angiogenesis-related diseases by significantly inhibiting angiogenesis. Or it is possible to treat.
- the invention provides a nucleic acid encoding an anti-C-KIT antibody or antibody fragment thereof.
- the nucleic acid encoding the anti-C-KIT antibody or antibody fragment thereof according to the present invention may include the nucleotide sequence of SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11.
- the nucleotide sequences of SEQ ID NO: 9, SEQ ID NO: 10 and SEQ ID NO: 11 encode light chain CDR1 represented by SEQ ID NO: 1, light chain CDR2 represented by SEQ ID NO: 2, and light chain CDR3 represented by SEQ ID NO: 3, respectively.
- nucleotide sequences of SEQ ID NOs: 9 to 11 may be codon optimized for CHO cells, respectively, and the nucleic acid comprising the codon optimized nucleotide sequence is a nucleic acid encoding an anti-C-KIT antibody or antibody fragment thereof according to the present invention It should be interpreted as being included within the scope of.
- a nucleic acid encoding an anti-C-KIT antibody or antibody fragment thereof according to the present invention may include SEQ ID NO: 17, SEQ ID NO: 18 and SEQ ID NO: 19.
- the nucleic acid encoding the anti-C-KIT antibody or antibody fragment thereof according to the present invention may include the nucleotide sequence of SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14.
- the base sequences of SEQ ID NO: 12, SEQ ID NO: 13 and SEQ ID NO: 14 encode heavy chain CDR1 represented by SEQ ID NO: 4, heavy chain CDR2 represented by SEQ ID NO: 5, and heavy chain CDR3 represented by SEQ ID NO: 6, respectively.
- nucleotide sequences of SEQ ID NOs: 12 to 14 may be codon optimized for CHO cells, respectively, and the nucleic acid comprising the codon optimized nucleotide sequence is a nucleic acid encoding an anti-C-KIT antibody or antibody fragment thereof according to the present invention It should be interpreted as being included within the scope of.
- a nucleic acid encoding an anti-C-KIT antibody or antibody fragment thereof according to the present invention may include SEQ ID NO: 20, SEQ ID NO: 21 and SEQ ID NO: 22.
- the nucleic acid encoding the anti-C-KIT antibody or antibody fragment thereof according to the present invention may include a light chain variable region encoding nucleic acid comprising SEQ ID NO: 15 or SEQ ID NO: 23.
- the nucleic acid encoding the anti-C-KIT antibody or antibody fragment thereof according to the present invention may include a heavy chain variable region encoding nucleic acid comprising SEQ ID NO: 16 or SEQ ID NO: 24.
- the nucleic acid encoding the anti-C-KIT antibody or antibody fragment thereof according to the present invention may include a light chain encoding nucleic acid comprising SEQ ID NO: 27 or SEQ ID NO: 29.
- the nucleic acid encoding the anti-C-KIT antibody or antibody fragment thereof of the present invention may include a heavy chain encoding nucleic acid comprising SEQ ID NO: 28 or SEQ ID NO: 30.
- nucleic acid as used herein has the meaning of comprehensively including DNA (gDNA and cDNA) and RNA.
- the nucleotides constituting the basic structural unit in a nucleic acid molecule include natural nucleotides, as well as analogues modified with sugar or base sites (Scheit, Nucleotide Analogs, John Wiley, New York (1980); Uhlman and Peyman, Chemical) Reviews, 90: 543-584 (1990)).
- the nucleic acid molecule encoding the anti-C-KIT antibody or antibody fragment thereof of the present invention includes a nucleotide sequence exhibiting substantial identity to the nucleotide sequence described above.
- the substantial identity means that the two sequences are aligned so as to correspond as much as possible, and after analysis using an algorithm commonly used in the art, 80%, 90%, or 95% or more of sequences are exhibited.
- the present invention provides a vector containing the nucleic acid and a cell transformed with the vector.
- the term “vector” means anything that can be inserted into a host cell and capable of gene replication.
- examples of such vectors include plasmids, linear nucleic acids, cosmids, RNA vectors, and viral vectors, and the viral vectors include, but are not limited to, retroviruses, adenoviruses, adeno-associated viruses, and the like.
- the recombinant vector system of the present invention can be constructed through various methods known in the art.
- the vector of the present invention can be constructed as a vector for cloning or expression, and can be constructed using prokaryotic or eukaryotic cells as hosts.
- the cells may be prokaryotic cells, eukaryotic cells or animal cells.
- Properly selected host cells can be transformed with the vector and used to express and / or secrete target proteins.
- the host cell may be immortalized hybridoma cells, N / SO myeloma cells, 293 cells, HuT 78 cells, CHO cells, HELA cells, COS cells, and the like, preferably CHO cells.
- any host cell known in the art can be used as the host cell of the present invention.
- the present invention provides a pharmaceutical composition for the prevention or treatment of angiogenesis-related diseases comprising an anti-C-KIT antibody or antibody fragment thereof.
- an angiogenesis of a subject comprising administering an anti-C-KIT antibody or an antibody fragment thereof or a composition comprising the same to a subject in need of treatment or prevention of angiogenesis-related diseases It provides a method for treating or preventing a related disease.
- treatment means all that symptoms of angiogenesis-related diseases become improvement, reversal, cure, etc. by administration of the composition according to the present invention.
- prevention means all that becomes an inhibition, delay, prevention, etc. of the occurrence or recurrence of angiogenesis-related diseases by administration of the composition according to the present invention.
- angiogenesis-related disease refers to a disease resulting from angiogenesis.
- diseases include cancer, leukemia, vascular-related diseases, rheumatoid arthritis, psoriasis, chronic wounds, chronic salts, hemangioma, angiofibromas, vascular malformations, arteriosclerosis, vascular adhesions, vasculitis, purulent granulomas, bleb diseases, pulmonary hypertension, asthma, non Polyps, infectious diseases, inflammatory bowel diseases, periodontal diseases, peritoneal adhesions, endometrium, uterine bleeding, ovarian cysts, osteomyelitis, osteosis, sepsis and autoimmune diseases.
- it may be a cancer-related and vascular-related disease, but is not limited thereto.
- the cancer may include bone cancer, lung cancer, head cancer, cervical cancer, thyroid cancer, parathyroid cancer, non-small cell lung cancer, stomach cancer, liver cancer, pancreatic cancer, skin cancer, melanoma of the skin or eyeball, rectal cancer, anal cancer, colon cancer, uterine cancer, breast cancer, Ovarian cancer, fallopian tube carcinoma, endometrial carcinoma, cervical carcinoma, vaginal carcinoma, vulvar carcinoma, Hodgkin's disease, esophageal cancer, small intestine cancer, endocrine adenocarcinoma, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, prostate cancer, bladder cancer, kidney It may be cancer or urinary tract cancer, renal cell carcinoma, renal pelvic carcinoma, central nervous system tumor, central nervous system lymphoma, spinal cord tumor, glioblastoma, brainstem glioma, pituitary adenoma.
- the vascular-related diseases may be diabetic retinopathy, macular degeneration, senile macular degeneration, glaucoma, glaucoma retinitis pigmentosa, choroidal neovascularization, retinopathy of prematurity, corneal dystrophy, and interlayer separation.
- the pharmaceutical composition according to the present invention may contain the anti-C-KIT antibody or a fragment thereof alone, or may further contain one or more pharmaceutically acceptable carriers, excipients or diluents.
- the pharmaceutically acceptable carrier may further include, for example, a carrier for oral administration or a carrier for parenteral administration.
- Carriers for oral administration may include lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like.
- the carrier for parenteral administration may include water, suitable oils, saline, aqueous glucose and glycol, and the like, and may further include stabilizers and preservatives. Examples of stabilizers are antioxidants such as sodium hydrogen sulfite, sodium sulfite or ascorbic acid. Examples of preservatives are benzalkonium chloride, methyl- or propyl-parabens and chlorobutanol.
- those known in the art can be used (Remington's Pharmaceutical Sciences, 19th ed, Mack Publishing Company, Easton, PA, 1995).
- the pharmaceutical composition of the present invention can be administered by any method to mammals, including humans. For example, it can be administered orally or parenterally.
- a parenteral administration method intravenous, intramuscular, intraarterial, intramedullary, intrathecal, intracardiac, transdermal, subcutaneous, intraperitoneal, intranasal, intestinal, topical, sublingual or rectal administration may be used. no.
- the pharmaceutical composition of the present invention may be administered as a method of preparing the injection-type formulation, lightly pricking the skin with a 30-gauge thin injection needle, or directly applying to the skin.
- the pharmaceutical composition of the present invention may be formulated as a formulation for oral administration or parenteral administration according to the administration route as described above.
- the compositions of the present invention may be formulated using methods known in the art as powders, granules, tablets, pills, dragees, capsules, liquids, gels, syrups, slurries, suspensions, etc. You can.
- oral preparations can obtain tablets or dragees by blending the active ingredient with a solid excipient and then grinding it and adding a suitable adjuvant to the granule mixture.
- excipients examples include sugars including lactose, dextrose, sucrose, sorbitol, mannitol, xylitol, erythritol and maltitol, and starches including corn starch, wheat starch, rice starch, potato starch, etc., cellulose, methyl Fillers such as cellulose, gelatin, polyvinylpyrrolidone and the like may be included, including cellulose, sodium carboxymethylcellulose and hydroxy propylmethyl-cellulose. In addition, if necessary, cross-linked polyvinylpyrrolidone, agar, alginic acid or sodium alginate may be added as a disintegrant.
- the pharmaceutical composition of the present invention may further include an anti-coagulant, a lubricant, a wetting agent, a flavoring agent, an emulsifying agent and a preservative.
- an anti-coagulant for parenteral administration, injection, cream, lotion, external ointment, oil, moisturizer, gel, aerosol and nasal inhaler may be formulated by methods known in the art. These formulations are described in Remington's Pharmaceutical Science, 15th Edition, 1975 Mack Publishing Company, Easton, Pennsylvania 18042, Chapter 87: Blaug, Seymour, generally known in all pharmaceutical chemistry.
- the total effective amount of the pharmaceutical composition of the present invention can be administered to a patient in a single dose, and can be administered by a fractionated treatment protocol that is administered for a long time in multiple doses.
- the pharmaceutical composition of the present invention can vary the content of the active ingredient according to the severity of the disease.
- the daily dosage of the pharmaceutical composition of the present invention may be 0.0001 to 100 mg / kg.
- the dosage of the pharmaceutical composition of the present invention considers the effective dosage for the patient in consideration of various factors such as the administration route and the number of treatments, as well as the patient's age, weight, health status, sex, disease severity, diet and excretion rate.
- the pharmaceutical composition according to the present invention is not particularly limited in its formulation, route of administration and method of administration as long as it shows the effects of the present invention.
- composition of the present invention may be administered as an individual therapeutic agent or in combination with other therapeutic agents.
- composition of the present invention and other therapeutic agents may be administered simultaneously, individually or sequentially.
- the other therapeutic agent may be a substance that is already known to have an effect of treating or improving angiogenesis-related diseases, and includes all other anticancer therapies other than drug therapy such as radiation therapy.
- the anti-C-KIT antibody and other therapeutic agents contained in the composition of the present invention may be formulated separately in separate containers or formulated together in the same container. You can.
- the present invention provides a kit for diagnosing angiogenesis-related diseases comprising an anti-C-KIT antibody or antibody fragment thereof.
- biological sample includes, but is not limited to, tissue, cell, blood, serum, plasma, and tissue autopsy samples (brain, skin, lymph nodes, spinal cord), and the like.
- the antibody of the present invention can be reacted with a biological sample to diagnose whether or not an angiogenesis-related disease has occurred.
- the anti-C-KIT antibody or functional fragment thereof can be diagnosed by contacting a biological sample to confirm whether an antigen-antibody complex is formed.
- the diagnostic kit of the present invention contains an antibody, it can be constructed to be suitable for various immunoassays or immunostaining.
- the immunoassay or immunostaining includes enzyme immunoassay (ELISA), immunofluorescence, western blotting, immunohistochemistry staining, flow cytometry, immunocytochemistry, and radioactivity.
- Labels for qualitatively or quantitatively measuring whether an antigen-antibody complex is formed include, but are not limited to, enzymes, fluorescent substances, ligands, luminescent substances, microparticles, redox molecules, and radioactive isotopes. .
- the novel anti-C-KIT antibody or antibody fragment thereof according to the present invention specifically binds to specific domain II of C-KIT and has a strong affinity. Accordingly, the antibody or antibody fragment thereof according to the present invention has a very good effect of significantly suppressing the production of abnormal or excessive angiogenesis, and can effectively prevent or treat angiogenesis-related diseases. In addition, the antibody or antibody fragment thereof according to the present invention can be effectively used in the study of angiogenesis-related diseases since it is cross-reactive to mice and rats in addition to humans.
- 1 is a graph showing the tube formation inhibitory effect of a total of 15 anti-C-KIT monoclonal antibodies when treated with SCF with HUVEC cells at a relative level compared to a non-treated control group.
- 2 is a graph showing the effect of inhibiting tube formation by concentration of 2G4 antibody when treated with SCF in HUVEC cells at a relative level compared to a non-treated control group.
- 3 is a graph showing the inhibitory effect of tube formation by concentration of 2G4 antibody when mouse-derived endothelial cell MS-1 is treated with SCF.
- 4 and 5 show the light chain variable region and heavy chain variable region bands of the 2G4 antibody, respectively.
- Figure 6 shows the nucleotide sequence, amino acid sequence and CDR region of the light chain variable region of the 2G4 antibody.
- FIG 7 shows the nucleotide sequence, amino acid sequence and CDR region of the heavy chain variable region of the 2G4 antibody.
- 9 is a graph showing the results of SPR analysis to confirm the C-KIT affinity of the 2G4 antibody.
- FIG. 11 shows the results of comparing the abnormal angiogenesis inhibitory ability of 2G4 antibody and commercially available Eylea using a mouse oxygen-induced retinopathy model.
- Figure 12 shows the results of comparing the abnormal angiogenesis inhibitory ability of 2G4 antibody and commercially available Eylea using a Brown Norway rat macular degeneration model.
- Figure 14 shows the inhibitory ability of 2G4 antibody against AKT phosphorylation, C-KIT phosphorylation, ERK 1/2 phosphorylation and ⁇ -catenin in the TF-1 cell line, thereby showing leukemia cell proliferation inhibition.
- An emulsion was prepared by mixing 50 ⁇ g (based on 1 mouse) of recombinant C-KIT protein (cat # PKSH030939) purchased from Elabscience with the same volume of Complete Freund's Adjuvant (sigma, USA). The emulsion thus prepared was injected into the peritoneal cavity of 6 humanized NSG mice produced by 7 week old female human CD34 + cell injection. 50 ⁇ g of antigen was injected into each mouse in a total volume of 500 ⁇ l. After 1 week and 2 weeks, the emulsion in which the antigen was mixed with the incomplete Freund's adjuvant (Sigma, USA) was additionally injected into the intraperitoneal cavity of the mouse.
- Blood was collected from the eyeballs of the immunized mice through the above method, placed in a 1.5 ml microcentrifuge tube, and centrifuged at 13,000 rpm for 10 minutes. Serum was isolated and stored at -20 ° C until an experiment to confirm antibody production was performed. After confirming the production of the antibody by performing an enzyme immunoassay using an antigen protein, an emulsion in which an incomplete Freund's adjuvant (Sigma, USA) and an antigen were mixed 3 days before cell fusion was injected into the mouse intraperitoneally once more.
- an enzyme immunoassay using an antigen protein
- an emulsion in which an incomplete Freund's adjuvant (Sigma, USA) and an antigen were mixed 3 days before cell fusion was injected into the mouse intraperitoneally once more.
- mice were cultured in a culture plate.
- P3X63Ag 8.653 cells were washed twice with serum-free RPMI1640 medium (Hyclone, USA) and adjusted to a concentration of 1x10 7 cells.
- the mice were sacrificed by cervical dislocation and spleens were collected, the cells were placed in a mesh container (Sigma, USA) to separate the cells. After preparing a suspension of spleen cells, the suspension was washed using centrifugation.
- Red blood cells were lysed by exposing the spleen cell solution to Tris-NH 4 Cl (TRIS 20.6 g / L, NH 4 Cl 8.3 g / L). The completely isolated antibody-producing cells were centrifuged at 400xg for 5 minutes. Then washed twice in serum free medium and resuspended in 10 ml medium. Lymphocytes were counted using a hemocytometer and lymphocytes 1x10 8 were mixed with P3X63Ag 8.653 cells 1x10 (10: 1) in serum-free medium.
- Tris-NH 4 Cl Tris-NH 4 Cl
- a 1 ml solution was added dropwise using 50% (M / V) polyethylene glycol 1500 (sigma, USA) warmed at 37 ° C and mixed for 1 minute.
- the fusion mixed solution thus prepared was diluted with serum-free RPMI1640 and centrifuged at 400xg for 3 minutes.
- Cells were suspended in 35 ml RPMI1640 selective medium supplemented with 20% fetal calf serum and HAT (100 ⁇ M hypoxanthine, 0.4 ⁇ M aminopterin, 16 ⁇ M thymidine).
- ⁇ l of the suspension was loaded on a 96-well plate coated with feeder cells (macrophages isolated from the peritoneal cavity using RPMI1640) one day before and incubated at 37 ° C., 5% CO 2 .
- HAT medium was replaced every 2-3 days, and the cells were cultured for 14 days.
- secondary culture was performed by replacing with RPMI1640 medium supplemented with 20% fetal bovine serum and HT (a medium with 0.4 ⁇ M aminopterin removed from HAT).
- the supernatant of the previously prepared fused cell culture was collected and enzymatic immunoassay was performed to confirm whether or not an antibody specific for the prepared antigen was produced.
- the culture medium of the fusion cells showing an appropriate concentration of 4 times or more compared to the negative control group was selected, and transferred to a 24-well plate and cultured.
- the culture medium was collected by diluting (limiting dilution) one cell per well into a 96-well plate, and the culture solution was recovered, and the C-KIT protein used as an antigen was coated at 0.1 ⁇ g per well.
- HUVEC Human Umbilical Vein Endothelial Cells
- SCF 50 ng / ml
- SCF 50 ng / ml + anti-C -KIT antibody
- HUVECs were SCF (50 ng / ml), SCF (50 ng / ml) + 2G4 antibody (0.1 ⁇ g / ml) or SCF (50 ng / ml) + 2G4 antibody (1 ⁇ g / ml) was dispensed into Matrigel. Thereafter, tube formation of HUVEC was observed, and the results are shown in FIG. 2.
- Example 2-2 To test the cross-reactivity of the 2G4 antibody to the mouse, the same procedure as in Example 2-2 was performed using mouse-derived endothelial cells MS-1.
- the kappa light chain domain was amplified from the cDNA using a human IgG library primer set from PROGEN.
- the amplified nucleic acid was confirmed by agarose gel electrophoresis, and the results are shown in FIG. 4.
- the heavy chain domain was similarly amplified using a human IgG library primer set from PROGEN, and the results are shown in FIG. 5.
- the PCR product was developed on an agarose gel, the band was cut, and the agarose gel was dissolved at 60 ° C., and nucleic acid was purified using a spin column (Qiagen) .
- the purified nucleic acid was cloned into a TOPO-TA vector, transformed into E. coli DH5 ⁇ to obtain colonies, and the colonies were cultured to extract plasmids.
- the nucleotide sequence of the 2G4 antibody was analyzed.
- FIG. 6 shows the amino acid sequence and nucleotide sequence of the light chain variable region of the 2G4 antibody, which correspond to the amino acid sequence of SEQ ID NO: 7 and the nucleotide sequence of SEQ ID NO: 15 in the Sequence Listing attached to the present specification, respectively.
- CDR1, CDR2 and CDR3 of the light chain variable region are shown in order in red, which is the amino acid sequence of SEQ ID NOs: 1 to 3 and the nucleotide sequence of SEQ ID NOs: 9 to 11, respectively, in the sequence list attached to the present specification.
- FIG. 7 shows the amino acid sequence and nucleotide sequence of the heavy chain variable region of the 2G4 antibody, which correspond to the amino acid sequence of SEQ ID NO: 8 and the nucleotide sequence of SEQ ID NO: 16 in the Sequence Listing attached to this specification, respectively.
- CDR1, CDR2 and CDR3 of the heavy chain variable region in FIG. 7 are shown in order in red color, which are the amino acid sequences of SEQ ID NOs: 4 to 6 and the nucleotide sequences of SEQ ID NOs: 12 to 14 in the sequence list attached to the present specification, respectively.
- variable region of the 2G4 antibody obtained in Example 3 was grafted to a human Fc amino acid sequence, and cloned into a pCHO vector (lifetechnology).
- the light chain variable region was fused in the frame for the human kappa constant region, and the heavy chain variable region was fused in the frame for the human IgG1 constant region.
- the genes were synthesized, and then verified once again through sequencing.
- Three clones were selected for expression testing in CHO cells. Glycerol stocks for 3 clones were prepared and endotoxin-free plasmids were prepared for CHO cell expression testing.
- the plasmid DNA obtained above was transfected into CHO-S cells.
- CHO-S cells Invitrogen, 10743-029
- DMEM supplemented serum was transferred into monolayer cultures in DMEM supplemented serum.
- the nucleic acid-lipofectamine complex was prepared for the transfected samples, and the cells were incubated at 5% CO 2 and 37 ° C. in an incubator overnight.
- the medium was incubated for one week with additions once every 2-3 days. Thereafter, the culture solution was collected, bound to Protein A / G agarose (Invitrogen), and washed with PBS. Then, after eluting with 0.1 M glycine (pH 2.8), neutralized with 1 M Tris-HCl (pH 8.0). After dialysis with PBS, it was stored at -70 ° C.
- the purified and purified 2G4 antibody was run on 6% SDS-PAGE under Non-reducing and Reducing conditions to confirm the purity and size of the antibody.
- the results are shown in FIG. 8.
- the SDS-PAGE result confirmed that a heavy chain band of 50 kDa and a light chain band of 25 kDa were observed, thereby confirming that the antibody was correctly produced.
- the results are shown in FIG. 9.
- the 2G4 antibody showed a strong affinity with a K D value for human C-KIT of about 2.8237 ( ⁇ 0.9) X 10 -12 M. It has the highest affinity for humans, followed by mouse and rat.
- Deletion variant of human C-KIT gene (NM_000222) (Q26-P520, D113-P520 ⁇ domain I, A207-P520 ⁇ domain I-II, K310-P520 ⁇ domain I-III) was tagged with FLAG at the c-terminus HEK293 was transfected. Then, it was secreted into the culture medium and then purified using FLAG antibody beads (Sigma-Aldrich). Next, ELISA was performed.
- the 2G4 antibody did not recognize C-KIT when the domain II was deleted, from which it was proved that the specific binding site for the C-KIT of the 2G4 antibody was domain II.
- OIR oxygen-induced retinopathy
- C57BL / 6 mice were exposed to an oxygen environment of 21% from 0 to 7 days of age and 75% to high oxygen environment from 7 to 12 days of age.
- 2G4 antibody (2 ⁇ g / eye) and Eylea (2 ⁇ g / eye) were injected intravitreally into the right eye, respectively, and the left eye was injected with PBS to compare as a control.
- exposure was again made to an oxygen environment of 21%, and sacrifice was made on the 17th day of life.
- abnormal angiogenesis inhibition was observed in the right eye injected with 2G4 antibody and Eylea (2 ⁇ g / eye), and the degree was confirmed to be an equivalent level.
- a macular degeneration model was constructed using brown Norway rats.
- CNV choroidal neovascularization
- 2G4 antibodies (6.28 ⁇ g / eye) and Eylea (10 ⁇ g / eye) were injected intravitreally into the eye at a dose of 4 ⁇ l / eye, respectively.
- SCF / C-KIT signaling is known to induce phosphorylation of AKT basically. As can be seen in Figure 13, it was confirmed that the phosphorylation of AKT increases when HCFEC is treated with SCF. On the other hand, it was confirmed that AKT phosphorylation was reduced by 2G4 antibody.
- FIG. 14 it can be confirmed from FIG. 14 that the AKT phosphorylation by SCF is inhibited by the 2G4 antibody in the leukemia cell line TF-1. Furthermore, it can be seen from FIG. 14 that phosphorylation of C-KIT by SCF and phosphorylation of ERK1 / 2 are also inhibited.
- ⁇ -catenin is an AKT downstream signal and is known to be an important factor for cell proliferation. It can be seen in FIG. 14 that the 2G4 antibody inhibits the increase of ⁇ -catenin by SCF in a concentration-dependent manner, which means that the 2G4 antibody significantly inhibits the proliferation of the leukemia cell line TF-1. Leukemia has many C-KIT mutations, so many cases of anti-cancer drug resistance or resistance are found, but the antibody according to the present invention can also exhibit a preventive or therapeutic effect against leukemia, thereby overcoming the limitations of conventional anti-cancer drugs.
- Example 8 Inhibition of HUVEC and TF-1 cell proliferation by 2G4 antibody
- 2G4 antibodies against TF-1 and HUVEC were pre-treated for 30 minutes by concentration (0, 0.1, 1, 5, 10 ⁇ g / ml). Thereafter, 50 ng / ml of SCF was treated, and the cell proliferation rate was compared by measuring the cell number after 36 hours.
- the group treated with SCF increased the number of TF-1 cells by about 26% and increased the number of HUVEC cells by about 70% compared to the negative control group.
- the group treated with 2G4 antibody cell proliferation by SCF was inhibited in a concentration-dependent manner in both TF-1 and HUVEC. This means that the 2G4 antibody has excellent HUVEC and TF-1 cell proliferation inhibitory ability.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- General Physics & Mathematics (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Oncology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
Description
Claims (13)
- C-KIT의 도메인 II에 특이적으로 결합하는 것을 특징으로 하는, 항-C-KIT 항체 또는 이의 항체 단편.
- 제1항에 있어서,상기 항체는 서열번호 1로 표시되는 경쇄 CDR1, 서열번호 2로 표시되는 경쇄 CDR2 및 서열번호 3으로 표시되는 경쇄 CDR3을 포함하는 경쇄 가변영역; 및 서열번호 4로 표시되는 중쇄 CDR1, 서열번호 5로 표시되는 중쇄 CDR2 및 서열번호 6으로 표시되는 중쇄 CDR3을 포함하는 중쇄 가변영역;을 포함하는 것을 특징으로 하는, 항-C-KIT 항체 또는 이의 항체 단편.
- 제1항에 있어서,상기 항체는 서열번호 7의 아미노산 서열을 포함하는 경쇄 가변영역; 및 서열번호 8의 아미노산 서열을 포함하는 중쇄 가변영역;을 포함하는 것을 특징으로 하는, 항-C-KIT 항체 또는 이의 항체 단편.
- 제1항에 있어서,상기 항체는 인간 IgG1 유래 불변영역을 포함하는 것을 특징으로 하는, 항-C-KIT 항체 또는 이의 항체 단편.
- 제1항의 항-C-KIT 항체 또는 이의 항체 단편을 코딩하는 핵산.
- 제5항에 있어서,상기 핵산은 (i) 서열번호 9 내지 14, (ii) 서열번호 15 및 16, (iii) 서열번호 17 내지 22, 또는 (iv) 서열번호 23 및 24를 포함하는 것을 특징으로 하는 핵산.
- 제5항의 핵산을 포함하는 벡터.
- 제7항의 벡터로 형질전환된 세포.
- 제1항의 항-C-KIT 항체 또는 이의 항체 단편을 포함하는, 혈관신생 관련 질환의 예방 또는 치료용 약학 조성물.
- 제9항에 있어서,상기 혈관신생 관련 질환은 암, 백혈병, 안혈관 질환, 류마티스 관절염, 건선, 만성 상처, 만성 염, 혈관종, 혈관섬유종, 혈관기형, 동맥경화, 혈관유착, 혈관염, 화농성 육아종, 수포질환, 폐고혈압증, 천식, 비폴립, 감염성 질환, 염증성 장 질환, 치주 질환, 복막 유착, 자궁내막, 자궁출혈, 난소낭종, 골수염, 골증, 패혈증 및 자가면역질환으로 이루어진 군으로부터 선택된 것을 특징으로 하는 약학 조성물.
- 제10항에 있어서,상기 암은 골암, 폐암, 두부암, 경부암, 갑상선암, 부갑상선암, 비소세포성폐암, 위암, 간암, 췌장암, 피부암, 피부 또는 안구내 흑색종, 직장암, 항문부근암, 결장암, 자궁암, 유방암, 난소암, 나팔관암종, 자궁내막암종, 자궁경부암종, 질암종, 음문암종, 호지킨병, 식도암, 소장암, 내분비선암, 부신암, 연조직 육종, 요도암, 음경암, 전립선암, 방광암, 신장암, 수뇨관암, 신장세포 암종, 신장골반 암종, 중추신경계 종양, 중추신경계 림프종, 척수 종양, 교모세포종, 뇌간 신경교종 및 뇌하수체 선종으로 이루어진 군으로부터 선택된 것을 특징으로 하는 약학 조성물.
- 제10항에 있어서,상기 안혈관 질환은 당뇨성 망막병, 황반변성, 노인성 황반변성, 녹내장, 녹내장성 망막색소변성, 맥락막 혈관신생, 미숙망막증, 각막 이영양증 및 망막층간분리로 이루어진 군으로부터 선택된 것을 특징으로 하는 약학 조성물.
- 제1항의 항-C-KIT 항체 또는 이의 항체 단편을 포함하는 혈관신생 관련 질환 진단용 키트.
Priority Applications (8)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA3116154A CA3116154A1 (en) | 2018-10-10 | 2019-10-10 | Novel anti-c-kit antibody |
BR112021006924-0A BR112021006924A2 (pt) | 2018-10-10 | 2019-10-10 | novo anticorpo anti-c-kit |
JP2021545343A JP2022508747A (ja) | 2018-10-10 | 2019-10-10 | 新規抗-c-kit抗体 |
EP19870797.8A EP3865512A4 (en) | 2018-10-10 | 2019-10-10 | NEW ANTI-C-KIT ANTIBODIES |
AU2019358647A AU2019358647A1 (en) | 2018-10-10 | 2019-10-10 | Novel anti-c-kit antibody |
US17/284,672 US20210355212A1 (en) | 2018-10-10 | 2019-10-10 | Novel anti-c-kit antibody |
EA202190983A EA202190983A1 (ru) | 2018-10-10 | 2019-10-10 | Новое антитело к с-kit |
CN201980079885.XA CN113166256A (zh) | 2018-10-10 | 2019-10-10 | 一种新型抗c-kit抗体 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020180120233A KR20200040407A (ko) | 2018-10-10 | 2018-10-10 | 신규 항-c-KIT 항체 |
KR10-2018-0120233 | 2018-10-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2020076105A1 true WO2020076105A1 (ko) | 2020-04-16 |
Family
ID=70164222
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2019/013310 WO2020076105A1 (ko) | 2018-10-10 | 2019-10-10 | 신규 항-c-kit 항체 |
Country Status (10)
Country | Link |
---|---|
US (1) | US20210355212A1 (ko) |
EP (1) | EP3865512A4 (ko) |
JP (1) | JP2022508747A (ko) |
KR (1) | KR20200040407A (ko) |
CN (1) | CN113166256A (ko) |
AU (1) | AU2019358647A1 (ko) |
BR (1) | BR112021006924A2 (ko) |
CA (1) | CA3116154A1 (ko) |
EA (1) | EA202190983A1 (ko) |
WO (1) | WO2020076105A1 (ko) |
Cited By (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023287251A1 (ko) | 2021-07-16 | 2023-01-19 | 주식회사 노벨티노빌리티 | Hif-1 알파 저해제 |
WO2023059113A1 (en) * | 2021-10-07 | 2023-04-13 | Novelty Nobility Inc. | Treatment of mast cell related disorders |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
WO2023146293A1 (ko) * | 2022-01-26 | 2023-08-03 | 주식회사 노벨티노빌리티 | C-kit을 표적으로 하는 면역접합체 |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023157989A1 (ko) * | 2022-02-17 | 2023-08-24 | 주식회사 노벨티노빌리티 | 항체-약물 접합체 |
CN114397453B (zh) * | 2022-03-25 | 2022-06-07 | 江苏美克医学技术有限公司 | 新型冠状病毒突变株的检测试剂盒及其应用 |
KR102572039B1 (ko) * | 2022-04-18 | 2023-08-30 | 주식회사 노벨티노빌리티 | 슈도모나스 외독소 A를 포함하는 c-Kit 표적 면역접합체 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140027239A (ko) * | 2011-05-12 | 2014-03-06 | 임클론 엘엘씨 | c-KIT 항체 및 이의 용도 |
KR20150038278A (ko) * | 2012-07-25 | 2015-04-08 | 콜탄 파마슈티컬스 인코포레이티드 | 항-kit 항체 및 그의 용도 |
KR20150131173A (ko) * | 2013-03-15 | 2015-11-24 | 노파르티스 아게 | 항체 약물 접합체 |
US20180193475A1 (en) * | 2014-08-05 | 2018-07-12 | Novartis Ag | Ckit antibody drug conjugates |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2508214A1 (en) * | 2002-12-02 | 2004-06-17 | Abgenix, Inc. | Antibodies directed to phospholipase a2 and uses thereof |
US20120253017A1 (en) * | 2009-05-28 | 2012-10-04 | Victoria Ballard | Stem cell targeting |
US20130011406A1 (en) * | 2010-03-26 | 2013-01-10 | Kolltan Pharmaceuticals, Inc. | Anti-kit antibodies and uses thereof |
KR101384360B1 (ko) * | 2012-05-04 | 2014-04-14 | 아주대학교산학협력단 | Scf 또는 이의 수용체를 억제하는 물질을 포함하는 혈관 투과성 관련 질환의 치료 또는 예방용 조성물 |
-
2018
- 2018-10-10 KR KR1020180120233A patent/KR20200040407A/ko not_active Application Discontinuation
-
2019
- 2019-10-10 WO PCT/KR2019/013310 patent/WO2020076105A1/ko unknown
- 2019-10-10 JP JP2021545343A patent/JP2022508747A/ja active Pending
- 2019-10-10 EP EP19870797.8A patent/EP3865512A4/en active Pending
- 2019-10-10 EA EA202190983A patent/EA202190983A1/ru unknown
- 2019-10-10 CN CN201980079885.XA patent/CN113166256A/zh active Pending
- 2019-10-10 BR BR112021006924-0A patent/BR112021006924A2/pt unknown
- 2019-10-10 AU AU2019358647A patent/AU2019358647A1/en active Pending
- 2019-10-10 CA CA3116154A patent/CA3116154A1/en active Pending
- 2019-10-10 US US17/284,672 patent/US20210355212A1/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20140027239A (ko) * | 2011-05-12 | 2014-03-06 | 임클론 엘엘씨 | c-KIT 항체 및 이의 용도 |
KR20150038278A (ko) * | 2012-07-25 | 2015-04-08 | 콜탄 파마슈티컬스 인코포레이티드 | 항-kit 항체 및 그의 용도 |
KR20150131173A (ko) * | 2013-03-15 | 2015-11-24 | 노파르티스 아게 | 항체 약물 접합체 |
US20180193475A1 (en) * | 2014-08-05 | 2018-07-12 | Novartis Ag | Ckit antibody drug conjugates |
Non-Patent Citations (8)
Title |
---|
"Remington's Pharmaceutical Science", 1975, MACK PUBLISHING COMPANY, pages: 18042 |
"Remington's Pharmaceutical Sciences", 1995, MACK PUBLISHING COMPANY |
ANGIOGENESIS IN HEALTH, DISEASE AND MALIGNANCY, pages 33 - 36 |
CAMELIETJAIN, NATURE, vol. 407, 2000, pages 249 |
OKAYAMA, Y.: "Assessment of the anti-c-kit monoclonal antibody YB5.B8 in affinity magnetic enrichment of human lung mast cells", JOURNAL OF IMMUNOLOGICAL METHOD, 1994, XP023974668 * |
SCHEIT: "Nucleotide Analogs", 1980, JOHN WILEY |
See also references of EP3865512A4 |
UHLMANPEYMAN, CHEMICAL REVIEW, vol. 90, 1990, pages 543 - 584 |
Cited By (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021130638A1 (en) | 2019-12-24 | 2021-07-01 | Carna Biosciences, Inc. | Diacylglycerol kinase modulating compounds |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
WO2021163064A2 (en) | 2020-02-14 | 2021-08-19 | Jounce Therapeutics, Inc. | Antibodies and fusion proteins that bind to ccr8 and uses thereof |
WO2022271684A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271677A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271659A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023287251A1 (ko) | 2021-07-16 | 2023-01-19 | 주식회사 노벨티노빌리티 | Hif-1 알파 저해제 |
WO2023059113A1 (en) * | 2021-10-07 | 2023-04-13 | Novelty Nobility Inc. | Treatment of mast cell related disorders |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
WO2023077030A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2023122581A2 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023122615A1 (en) | 2021-12-22 | 2023-06-29 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023146293A1 (ko) * | 2022-01-26 | 2023-08-03 | 주식회사 노벨티노빌리티 | C-kit을 표적으로 하는 면역접합체 |
WO2023147418A1 (en) | 2022-01-28 | 2023-08-03 | Gilead Sciences, Inc. | Parp7 inhibitors |
EP4245756A1 (en) | 2022-03-17 | 2023-09-20 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023178181A1 (en) | 2022-03-17 | 2023-09-21 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
WO2023205719A1 (en) | 2022-04-21 | 2023-10-26 | Gilead Sciences, Inc. | Kras g12d modulating compounds |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Also Published As
Publication number | Publication date |
---|---|
EP3865512A4 (en) | 2022-08-03 |
AU2019358647A1 (en) | 2021-06-03 |
CN113166256A (zh) | 2021-07-23 |
US20210355212A1 (en) | 2021-11-18 |
JP2022508747A (ja) | 2022-01-19 |
KR20200040407A (ko) | 2020-04-20 |
CA3116154A1 (en) | 2020-04-16 |
EP3865512A1 (en) | 2021-08-18 |
BR112021006924A2 (pt) | 2021-07-20 |
EA202190983A1 (ru) | 2021-07-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2020076105A1 (ko) | 신규 항-c-kit 항체 | |
KR101671378B1 (ko) | c-Met에 특이적으로 결합하는 항체 및 그의 용도 | |
WO2015167293A1 (en) | Antibody binding to fcrn for treating autoimmune diseases | |
WO2021107566A1 (ko) | C-kit에 대한 항체 및 이의 용도 | |
EP3896085A1 (en) | Anti-human interleukin 5(il-5) monoclonal antibody and use thereof | |
WO2021228141A1 (zh) | 抗体药物缀合物及其制备方法和用途 | |
WO2021091359A1 (ko) | 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체 | |
WO2020098672A1 (zh) | 一种融合蛋白及其用途 | |
CN111868091A (zh) | 用抗tim3抗体治疗癌症的方法 | |
CN110563843A (zh) | 一种靶向人vista蛋白的单克隆抗体 | |
CN110642950B (zh) | 一种人源化t细胞活化的v域免疫抑制因子抗原结合片段 | |
WO2017074013A1 (ko) | 인간 및 마우스 sema3a에 교차결합하는 항체 및 그의 용도 | |
WO2016084993A1 (ko) | 신규 EGFRvIII 항체 및 이를 포함하는 조성물 | |
WO2022015113A1 (ko) | Ptk7에 특이적으로 결합하는 항체 및 이의 용도 | |
WO2019088658A1 (ko) | Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도 | |
WO2024106939A1 (ko) | B7-h3에 특이적으로 결합하는 항체 | |
CN110563848A (zh) | 一种双特异性抗体及其用途 | |
CN110563847A (zh) | 用于治疗性用途的免疫检查点抑制剂 | |
WO2018124851A1 (ko) | L1cam 단백질에 특이적으로 결합하는 항체; 및 피리미딘 유사체 및/또는 플라틴계 항암제를 포함하는 암의 예방 또는 치료용 약학적 조성물 | |
WO2024090927A1 (ko) | 신규 항-cdcp1 항체 및 이의 용도 | |
CN111875697B (zh) | 一种包含肽标签的融合蛋白 | |
WO2023136648A1 (ko) | 항-vegfr2(kdr) 개량 항체를 포함하는 융합단백질 및 이의 용도 | |
WO2023101438A1 (ko) | Smo 인간 항체 | |
WO2022244908A1 (ko) | 항-bcam 항체 또는 그의 항원 결합 단편 | |
WO2021244587A1 (zh) | 一种抗PD-L1/TGF-β融合蛋白 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 19870797 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2021545343 Country of ref document: JP Kind code of ref document: A Ref document number: 3116154 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112021006924 Country of ref document: BR |
|
ENP | Entry into the national phase |
Ref document number: 2019870797 Country of ref document: EP Effective date: 20210510 |
|
ENP | Entry into the national phase |
Ref document number: 2019358647 Country of ref document: AU Date of ref document: 20191010 Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112021006924 Country of ref document: BR Kind code of ref document: A2 Effective date: 20210412 |